Myofibroblast involvement in glycosaminoglycan synthesis and lipid retention during coronary repair.
Myofibroblasts of adventitial origin have been linked to neointimal formation and remodeling after coronary injury. Accordingly, the goal of this study was to examine whether myofibroblasts contribute to focal accumulation of glycosaminoglycans (GAGs) and lipids during coronary repair. GAG synthesis was assessed by ex vivo labeling of balloon-injured porcine coronary arteries with (14)C-glucosamine. The synthesis of total GAGs transiently increased at 8 days in the normolipemic model (a 2.2-fold increase over baseline, p < 0.05). The majority of newly synthesized GAGs were sensitive to chondroitin ABC lyase (chondroitin/dermatan sulfate GAGs). Versican was localized to myofibroblast-rich regions in the adventitia and neointima [positive for alpha-smooth muscle (SM) actin, negative for h-caldesmon and SM myosin heavy chain]. In contrast, the adjacent SM-rich media showed no increase in versican expression. The association between injury-induced GAG accumulation and lipid retention was examined at 2 weeks after coronary injury in the hyperlipemic model. Lipid (Oil Red O) accumulated in the neointima and adventitia, but not in the adjacent media. Coronary repair under hyperlipemic conditions was associated with macrophage infiltration (19 +/- 5 vs. 3 +/- 2% of neointimal cells in normolipemic animals, p < 0.001) and increased neointimal formation (1.8 +/- 0.5 vs. 1.0 +/- 0.3 mm(2) in normolipemic animals, p < 0.01). In conclusion, this study demonstrated a transient increase in GAG synthesis following coronary injury. Chondroitin sulfate proteoglycans (e.g., versican) were rapidly synthesized by activated adventitial and neointimal cells which could contribute to early lipid retention in injured vessels.
Shi
Y
Y
Division of Cardiology, Thomas Jefferson University, Philadelphia, PA 19107, USA. yi.shi@mail.tju.edu
Niculescu
R
R
Wang
D
D
Ormont
M
M
Magno
M
M
San Antonio
J D
JD
Williams
K J
KJ
Zalewski
A
A
D000818:Animals; D001391:Azo Compounds; D002404:Catheterization; D011508:Chondroitin Sulfate Proteoglycans / Q000032:analysis / Q000096:biosynthesis; D002809:Chondroitin Sulfates / Q000032:analysis; D003124:Colorimetry; D004396:Coloring Agents; D003331:Coronary Vessels / Q000737:chemistry / Q000293:injuries* / Q000378:metabolism; D003871:Dermatan Sulfate / Q000032:analysis; D005347:Fibroblasts / Q000502:physiology*; D006025:Glycosaminoglycans / Q000032:analysis / Q000096:biosynthesis*; D007150:Immunohistochemistry; D007700:Kinetics; D037181:Lectins, C-Type; D050356:Lipid Metabolism; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000502:physiology*; D013552:Swine; D053675:Versicans
D001391:Azo Compounds; D011508:Chondroitin Sulfate Proteoglycans; D004396:Coloring Agents; D006025:Glycosaminoglycans; D037181:Lectins, C-Type; D053675:Versicans; D003871:Dermatan Sulfate; D002809:Chondroitin Sulfates; C011049:oil red O